Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 10Endometrial Hyperplasia 5Neoplasms 4Cachexia 4Breast Neoplasms 4Anorexia 4Recurrence 2Vomiting 1Squamous Intraepithelial Lesions 1Spinal Cord Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Oligodendroglioma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Head and Neck Neoplasms 1Fatigue 1Familial ependymoma 1Dendritic Cell Sarcoma, Interdigitating 1Choroid Plexus Neoplasms 1

Interventions

Palonosetron 13Aprepitant 13Dexamethasone 11Ondansetron 10fosaprepitant 4Olanzapine 4Granisetron 3Calcium Dobesilate 3ramosetron 2netupitant 2Tropisetron 2Radiotherapy 2Fluorouracil 2rolapitant 1netupitant, palosentron drug combination 1ginger extract 1dolasetron 1casopitant 1Yoga 1Therapeutics 1Serotonin 5-HT3 Receptor Antagonists 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiation 1Pantoprazole 1Paclitaxel 1Oxaliplatin 1Octreotide 1Megestrol Acetate 1Megestrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vomiting × Megestrol Acetate × Clear all
NCT04430361 2020-06-12

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled

Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡